Cytoreductive surgery for men with metastatic prostate cancer

Gratzke, 2014, Role of radical prostatectomy in metastatic prostate cancer: data from the Munich Cancer Registry, Eur Urol, 66, 602, 10.1016/j.eururo.2014.04.009 Heidenreich, 2015, Cytoreductive radical prostatectomy in patients with prostate cancer and low volume skeletal metastases: results of a feasibility and case-control study, J Urol, 193, 832 Swanson, 2006, Metastatic prostate cancer-does treatment of the primary tumor matter?, J Urol, 176, 1292 Wiegand, 2011, Surgical management of lymph-node-positive prostate cancer: improves symptomatic control, BJU Int, 107, 1238, 10.1111/j.1464-410X.2010.09657.x Frohmuller, 1995, Survival and quality of life of patients with stage D1 (T1-3 pN1-2 M0) prostate cancer. Radical prostatectomy plus androgen deprivation versus androgen deprivation alone, Eur Urol, 27, 202, 10.1159/000475161 Stewart, 2015, Radical prostatectomy in high-risk and locally advanced prostate cancer: Mayo Clinic perspective, Urol Oncol, 33, 235, 10.1016/j.urolonc.2014.10.003 Ghavamian, 1999, Radical retropubic prostatectomy plus orchiectomy versus orchiectomy alone for pTxN+ prostate cancer: a matched comparison, J Urol, 161, 1223 Engel, 2010, Survival benefit of radical prostatectomy in lymph node-positive patients with prostate cancer, Eur Urol, 57, 754, 10.1016/j.eururo.2009.12.034 Steuber, 2011, Radical prostatectomy improves progression-free and cancer-specific survival in men with lymph node positive prostate cancer in the prostate-specific antigen era: a confirmatory study, BJU Int, 107, 1755, 10.1111/j.1464-410X.2010.09730.x Napieralska, 2014, The results of treatment of prostate cancer bone metastases after CyberKnife radiosurgery, Ortop Traumatol Rehabil, 16, 339, 10.5604/15093492.1112535 Afshar-Oromieh, 2015, The diagnostic value of PET/CT imaging with the Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer, Eur J Nucl Med Mol Imaging, 42, 197, 10.1007/s00259-014-2949-6 Afshar-Oromieh, 2013, PET imaging with a [68Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions, Eur J Nucl Med Mol Imaging, 40, 486, 10.1007/s00259-012-2298-2 Katelaris, 2015, Current role of multiparametric magnetic resonance imaging in the management of prostate cancer, Korean J Urol, 56, 337, 10.4111/kju.2015.56.5.337 Eiber, 2015, (68)Ga-PSMA PET/MR with multimodality image analysis for primary prostate cancer, Abdom Imaging, 40, 1769, 10.1007/s00261-014-0301-z